<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Insulin regular: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Insulin regular: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Insulin regular: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9030" href="/d/html/9030.html" rel="external">see "Insulin regular: Drug information"</a> and <a class="drug drug_patient" data-topicid="11771" href="/d/html/11771.html" rel="external">see "Insulin regular: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2105104"><span class="drugH1">Brand Names: US</span>
<ul>
<li>HumuLIN R U-500 (CONCENTRATED);</li>
<li>HumuLIN R U-500 KwikPen;</li>
<li>HumuLIN R [OTC];</li>
<li>Myxredlin;</li>
<li>NovoLIN R FlexPen ReliOn [OTC];</li>
<li>NovoLIN R FlexPen [OTC];</li>
<li>NovoLIN R ReliOn [OTC];</li>
<li>NovoLIN R [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868741"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Entuzity Kwikpen;</li>
<li>HumuLIN R;</li>
<li>HumuLIN R KwikPen;</li>
<li>Myxredlin;</li>
<li>NovoLIN GE Toronto;</li>
<li>NovoLIN GE Toronto Penfill</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F2983813"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidiabetic Agent, Parenteral</span>;</li>
<li>
<span class="list-set-name">Antidote</span>;</li>
<li>
<span class="list-set-name">Hyperkalemia, Adjunctive Treatment Agent</span>;</li>
<li>
<span class="list-set-name">Insulin, Short-Acting</span></li></ul></div>
<div class="block don drugH1Div" id="F53462639"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0548af2d-f964-4342-997c-4569fff5e8ba">Hyperglycemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperglycemia:</b> Limited data available: <b>Note:</b> Neonates are extremely sensitive to the effects of insulin; initiate therapy at the lower end of infusion rate and monitor closely; routine use in neonates is not recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: 0.05 to 0.1 units/kg infused over 15 minutes every 4 to 6 hours as needed; <b>Note:</b> Should be used as initial management; monitor blood glucose every 30 minutes to 1 hour following doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Initial rate: 0.01 to 0.05 units/kg/<b>hour</b>, monitor blood glucose every 30 minutes and titrate in 0.01 units/kg/<b>hour</b> increments, usual range: 0.01 to 0.1 units/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1','lexi-content-ref-Hemachandra.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1','lexi-content-ref-Hemachandra.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c38c267b-5990-4874-9850-e45ba5771599">Hyperkalemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, treatment: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 0.1 units/kg combined with dextrose. <b>Note:</b> Usual ratio is 1 unit of insulin for every 5 g of dextrose for intermittent IV doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Initial bolus: 0.05 units/kg in combination with dextrose followed by a continuous IV infusion of insulin at 0.1 unit/kg/<b>hour</b> in combination with dextrose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>); insulin infusions as low as 0.05 units/kg/<b>hour</b> in conjunction with dextrose infusion have been used in premature neonates (n=7; GA: ≤28 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1986079']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1986079'])">Ref</a></span>). <b>Note:</b> Usual ratio is 1 unit of insulin for every 2 to 4 g of dextrose for continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F2104987"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b> Insulin regular is a short-acting insulin formulation. Insulin doses should be individualized based on patient needs; adjustments may be necessary with changes in physical activity, meal patterns, acute illness, or with changes in renal or hepatic function. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision. Insulin regimens vary widely by region, practice, and institution; consult institution-specific guidelines.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5956846-9e6c-4def-954b-a126316b2bbe">Diabetes mellitus, type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1:</b> Infants, Children, and Adolescents: <b>Note:</b> Insulin regular is generally used concomitantly with intermediate- or long-acting insulin (ie, multiple daily injection regimen) or via a continuous SubQ insulin infusion pump. The daily doses presented are expressed as the total units/kg/day <b>of all insulin formulations combined</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>General insulin dosing:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial total daily insulin:</i> SubQ: Initial: 0.4 to 0.5 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020'])">Ref</a></span>); usual range: 0.4 to 1 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-15616254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-15616254'])">Ref</a></span>); lower doses (0.25 units/kg/day) may be used, especially in young children, to avoid potential hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472948'])">Ref</a></span>); higher doses may be necessary for some patients (eg, obese, concomitant steroids, puberty, sedentary lifestyle, following diabetic ketoacidosis presentation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-15616254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-15616254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Usual total daily maintenance range:</i> SubQ: Doses must be individualized; however, an estimate can be determined based on phase of diabetes and level of maturity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29999222','lexi-content-ref-28726299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29999222','lexi-content-ref-28726299'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Partial remission phase (Honeymoon phase): &lt;0.5 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Prepubertal children (not in partial remission):</p>
<p style="text-indent:-2em;margin-left:10em;">Infants ≥6 months and Children ≤6 years: 0.4 to 0.8 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥7 years: 0.7 to 1 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1 unit/kg/day and, in some cases, up to 2 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Division of daily insulin requirement (multiple daily injections):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Basal insulin: Generally, ~30% to 50% of the total daily insulin dose is given as basal insulin (intermediate- or long-acting) in 1 to 2 daily injections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-29999222','lexi-content-ref-Peters.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-29999222','lexi-content-ref-Peters.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Prandial insulin: The remaining portion of the total daily dose is then divided and administered before or at mealtimes (depending on the formulation) as rapid-acting (eg, aspart, glulisine, lispro) or short-acting (regular). In most type 1 patients, the use of a rapid-acting insulin analog is preferred over regular insulin to reduce hypoglycemia risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-24935775','lexi-content-ref-29999222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2020','lexi-content-ref-24935775','lexi-content-ref-29999222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dose titration:</b> Treatment and monitoring regimens must be individualized to maintain premeal and bedtime glucose in target range; titrate dose to achieve glucose control and avoid hypoglycemia. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Surgical patients </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30039617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30039617'])">Ref</a></span>)<i>:</i>
<b>Note: </b>Diabetic patients should be scheduled as the first case of the day.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Minor surgeries: <b></b></i></p>
<p style="text-indent:-2em;margin-left:10em;">Morning procedure: Omit short-acting insulin unless it is need to correct hyperglycemia and administer the usual morning dose of long-acting insulin or 50% to 70% of the usual morning dose of insulin NPH; alternatively, administer IV insulin (regular) infusion beginning at least 2 hours prior to surgery.</p>
<p style="text-indent:-2em;margin-left:10em;">Afternoon procedure: If allowed to eat breakfast, administer 50% of the usual morning dose of short-acting insulin (regular) with breakfast. Begin an IV insulin (regular) infusion beginning at least 2 hours prior to surgery.</p>
<p style="text-indent:-2em;margin-left:10em;">Postprocedure: Once normal oral intake is achieved, resume usual insulin regimen; monitor closely; insulin requirement may be higher due to risk of changes related to surgery (ie, postoperative stress, medication changes, inactivity).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Major surgeries:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Evening prior to surgery: Administer the usual evening and/or bedtime insulin(s); patients on continuous subcutaneous insulin infusion (CSII) may continue normal insulin basal rates overnight; if there is a concern for hypoglycemia, basal rate may be reduced by 20% at ~3 am.</p>
<p style="text-indent:-2em;margin-left:10em;">Morning of surgery: Omit morning insulin (short- and long-acting) and start IV insulin (regular) infusion and IV dextrose at least 2 hours prior to surgery; patients on CSII, should discontinue CSII when IV insulin infusion is started.</p>
<p style="text-indent:-2em;margin-left:10em;">Postprocedure: Once normal oral intake is achieved, resume usual insulin regimen; monitor closely; insulin requirement may be higher due to risk of changes related to surgery (ie, postoperative stress, medication changes, inactivity).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="570f091a-c1c1-46a6-9d95-172eadddf365">Diabetes mellitus, type 2</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2:</b> Children ≥10 years and Adolescents: SubQ: The goal of therapy is to achieve an HbA1c &lt;7% as quickly as possible using the safe titration of medications. Initial therapy in metabolically unstable patients (eg, plasma glucose ≥250 mg/dL, HbA1c ≥8.5% and symptoms excluding acidosis) may include once-daily long-acting basal insulin (preferred) or intermediate-acting insulin (eg, NPH) in combination with lifestyle changes and metformin. In patients who fail to achieve glycemic goals with metformin and basal insulin, may consider initiating prandial insulin (rapid-acting insulin or regular insulin in select situations) and titrate to achieve goals. Once initial goal reached, insulin should be slowly tapered over 2 to 6 weeks by decreasing the insulin dose by 10% to 30% every few days and the patient transitioned to lowest effective insulin doses or metformin monotherapy if able (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23359574','lexi-content-ref-ADA.2020','lexi-content-ref-30425094','lexi-content-ref-29999228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23359574','lexi-content-ref-ADA.2020','lexi-content-ref-30425094','lexi-content-ref-29999228'])">Ref</a></span>). <b>Note:</b> Patients who are ketotic or present with ketoacidosis require aggressive management with SubQ or IV insulin to correct the hyperglycemia and ketosis/ketoacidosis. Once ketosis/ketoacidosis resolves, metformin should be initiated as appropriate, while continuing insulin via the SubQ route; insulin can be titrated as appropriate once goals are achieved.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7e584e3-f53e-427f-8d94-6e75dea2899a">Diabetic ketoacidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic ketoacidosis (DKA):</b> Limited data available: Infants, Children, and Adolescents: <b>Note:</b> Severe DKA should be treated with IV regular insulin. Serum glucose is not a direct indicator of the overall metabolic abnormalities and may decrease more rapidly than correction of the metabolic abnormalities such as acid-base abnormalities, blood β-hydroxybutyrate (BOHB), and anion gap. As part of overall DKA management, dextrose should be added to IV fluids to prevent hypoglycemia, usually once serum glucose is between 250 to 300 mg/dL, but it may be required sooner if serum glucose has decreased precipitously. Generally, only dextrose 5% is necessary and is added to NS or <sup>1</sup>/<sub>2</sub>NS; however, dextrose 10% or 12.5% may be necessary in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16644656','lexi-content-ref-29900641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16644656','lexi-content-ref-29900641'])">Ref</a></span>). Refer to institution-specific protocols where appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial:</i> 0.05 to 0.1 units/kg/<b>hour</b> (start insulin infusion at least 1 hour after starting fluid replacement therapy); DO NOT bolus at start of therapy; continue the rate at 0.05 to 0.1 units/kg/hour, if tolerated, until resolution of ketoacidosis (pH &gt;7.3; bicarbonate &gt;15 mEq/L, BOHB &lt; 1 mmol/L, and/or closure of anion gap); serum BOHB should decrease by approximately 0.5 mmol/L/hour; adjust insulin if the expected rate of biochemical correction does not occur. <b>Note:</b> Some patients (eg, some young children with DKA, older children with established diabetes) may have marked sensitivity to insulin requiring lower infusion rates; these lower infusion rates should only be used provided that resolution of the acidosis continues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16644656','lexi-content-ref-29900641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16644656','lexi-content-ref-29900641'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transition from IV to SubQ insulin:</i> Once ketoacidosis has resolved and oral intake is tolerated, transition to a SubQ insulin regimen. An overlap between discontinuation of IV insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels. A dose of basal (long-/intermediate-acting) insulin should be administered in addition to rapid-/short-acting insulin. To prevent rebound hyperglycemia, adjust timing of SubQ insulin administration prior to infusion discontinuation dependent on type of insulin used; for SubQ regular insulin: 1 to 2 hours, or for rapid-acting insulin: 15 to 30 minutes; with intermediate- or long-acting insulin, the overlap should be longer and the rate of IV insulin administration gradually decreased (eg, administer basal in the evening and discontinue the IV infusion the next morning); optimal timing for transition is around mealtime for convenience. Benefits have been seen with early administration of basal insulin during IV insulin infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29900641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29900641'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">SubQ: <b>Note:</b> SubQ administration for DKA treatment may be considered for patients with uncomplicated DKA in whom peripheral circulation is adequate and continuous IV regular insulin administration is not possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29900641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29900641'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 0.8 to 1 unit/kg/day in divided doses every 4 hours; titrate dose by 10% to 20% based on blood glucose concentration prior to next insulin dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="451228b2-a130-4e28-b9c9-27f753f67cfb">Calcium channel blocker or beta-blocker toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium channel blocker or beta-blocker toxicity (high-dose insulin therapy):</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-30412709','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-30412709','lexi-content-ref-20956230'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consultation with a clinical toxicologist or poison control center is highly recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Prior to initiating high-dose insulin therapy, dextrose supplementation is necessary in infants and children with serum glucose &lt;400 mg/dL and in adolescents with serum glucose &lt;200 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-29452919','lexi-content-ref-21563902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-29452919','lexi-content-ref-21563902'])">Ref</a></span>). Monitor serum glucose closely during therapy, with increased frequency of monitoring following the initial insulin bolus and during insulin infusion rate changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34957477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34957477'])">Ref</a></span>). Concomitant dextrose infusion or intermittent dextrose boluses are necessary to prevent hypoglycemia; maintain euglycemia goal of 100 to 250 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>). When discontinuing the insulin infusion, the hypoglycemic effects may last for at least 24 hours after it is stopped; continue to monitor glucose levels closely during that time.</p>
<p style="text-indent:-2em;margin-left:6em;">Correct hypokalemia prior to initiation of insulin therapy; monitor serum potassium closely during insulin infusion and supplement as needed to maintain normal serum potassium levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21563902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21563902'])">Ref</a></span>). To avoid fluid overload, concentrate IV fluids, including dextrose boluses or supplementation as appropriate and as venous access allows (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21563902','lexi-content-ref-30141827','lexi-content-ref-34957477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21563902','lexi-content-ref-30141827','lexi-content-ref-34957477'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Initial loading dose: 0.5 to 1 unit/kg bolus followed by a continuous IV infusion starting at 0.5 to 1 unit/kg/hour; titrate to clinical response; it has been suggested if patient remains hypotensive after initial 30 minutes of infusion to increase rate to 2 units/kg/hour, with additional rate increases as needed to maintain normotension. In severe cases, higher doses (continuous infusion &gt;10 units/kg/hour) may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-29452919','lexi-content-ref-21563902','lexi-content-ref-10966679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-29452919','lexi-content-ref-21563902','lexi-content-ref-10966679'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c38c267b-5990-4874-9850-e45ba5771599">Hyperkalemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, treatment: </b>Limited data available: <b>Note:</b> Experts suggest using a ratio of 1 unit of insulin for every 5 g of dextrose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fuhrman.1','lexi-content-ref-21181208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fuhrman.1','lexi-content-ref-21181208'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 0.1 unit/kg (maximum dose: 10 units/dose) combined with dextrose administered over 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Cameron.1','lexi-content-ref-21181208','lexi-content-ref-21920871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Cameron.1','lexi-content-ref-21181208','lexi-content-ref-21920871'])">Ref</a></span>). An alternate approach is dextrose bolus followed by 0.2 units of insulin per g of dextrose administered over 15 to 30 minutes then infused continuously as a similar amount per hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fuhrman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fuhrman.1'])">Ref</a></span>). In adults, the usual dose is 10 units of insulin mixed with 25 g of dextrose (50 mL of D50W) administered over 15 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d7d792db-0729-404c-9665-cb8d41f8985a">Hyperosmolar hyperglycemic state</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperosmolar hyperglycemic state (HHS):</b> Limited data available: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Only regular IV insulin should be used. Insulin administration should be initiated when serum glucose concentration is no longer declining at a rate ≥50 mg/dL/hour with fluid administration alone; earlier initiation may be required in patients with severe ketosis and acidosis. Refer to institution-specific protocols where appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Initial: 0.025 to 0.05 units/kg/<b>hour</b>; titrate dose to achieve a decrease in serum glucose concentration at a rate of 50 to 75 mg/dL/hour; discontinue insulin if serum glucose concentration decreases &gt;100 mg/dL/hour. Insulin boluses are not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29900641','lexi-content-ref-21035820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29900641','lexi-content-ref-21035820'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114032"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements are reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely. Based on experience in adult patients, dosage adjustment may be necessary.</p></div>
<div class="block dohp drugH1Div" id="F51114033"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block doa drugH1Div" id="F2104988"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9030" href="/d/html/9030.html" rel="external">see "Insulin regular: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Regular insulin U-100 is <b>not </b>interchangeable with concentrated U-500 regular insulin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Regular insulin U-100 (100 units/mL) is a short-acting insulin, whereas concentrated U-500 regular insulin has an onset similar to short-acting insulins and a duration similar to intermediate-acting insulins. Insulin requirements vary between patients; monitor glucose levels frequently and individualize dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f0f08c28-c232-4eaf-b74b-04939d962ca9">Calcium channel blocker or beta-blocker overdose/toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium channel blocker or beta-blocker overdose/toxicity (off-label use): Note:</b> Optimal dosage regimen has not been determined; use for patients who are refractory to initial therapies (eg, atropine, calcium, vasopressors). Consultation with a clinical toxicologist or poison control center is highly recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (U-100):</b> 1 unit/kg bolus, followed by a continuous infusion at 0.5 to 1 unit/kg/hour (as premixed solution or diluted U-100 product for IV infusion) titrated to clinical response. Higher doses (eg, boluses of up to 10 units/kg and continuous infusions of &gt;10 units/kg/hour) have been administered with good outcomes and minimal adverse effects. Once hemodynamic parameters have stabilized, gradually decrease insulin infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30412709','lexi-content-ref-29452919','lexi-content-ref-21563902','lexi-content-ref-30141827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30412709','lexi-content-ref-29452919','lexi-content-ref-21563902','lexi-content-ref-30141827'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Correct hypokalemia prior to initiation of insulin therapy. For patients with baseline blood glucose &lt;200 mg/dL, administer 50 mL of dextrose 50% IV prior to initiation of insulin therapy. Start a dextrose infusion when insulin therapy is initiated to maintain euglycemia; maintain normokalemia and euglycemia during insulin infusion and after withdrawal of insulin. Monitor blood glucose and electrolytes frequently, especially at the initiation of therapy. Concentrate all IV fluids to avoid fluid overload (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29452919','lexi-content-ref-21563902','lexi-content-ref-30141827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29452919','lexi-content-ref-21563902','lexi-content-ref-30141827'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc2823b3-202c-4a44-a2d1-58b5084839e6">Diabetes mellitus, type 1, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Regular insulin must be used concomitantly with intermediate- or long-acting insulin (ie, multiple daily injections regimen) or in a continuous SUBQ infusion device. <b>The total daily doses (TDDs) presented below are expressed as the total units/kg/day of all insulin formulations combined.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General insulin dosing (off label):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Initial TDD:</i></b>
<b>SUBQ (U-100): </b>~0.4 to 0.5 units/kg/day in divided doses; conservative initial doses of 0.2 to 0.4 units/kg/day may be considered to avoid the potential for hypoglycemia; higher initial doses may be required in patients with obesity, or who are sedentary or presenting with ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Usual TDD maintenance range:</b></i>
<b>SUBQ (U-100): </b>0.4 to 1 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Division of TDD (multiple daily injections):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Basal insulin: Generally, 40% to 50% of the TDD is given as basal insulin (intermediate- or long-acting) in 1 to 2 daily injections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Prandial insulin: The remaining portion (ie, 50% to 60%) of the TDD is then divided and administered before, at, or just after mealtimes depending on the formulation (eg, short-, rapid-, ultra-rapid acting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Handelsman.1','lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Dosage adjustment: </b></i>Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen that most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Regular insulin U-100 is <b>not</b> interchangeable with concentrated U-500 regular insulin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Regimens involving regular insulin U-100 (100 units/mL):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>May be used if glycemic targets are not met despite adequately titrated basal insulin (eg, fasting glucose levels at goal, basal insulin dose &gt;0.5 units/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>). For regimens containing basal and prandial insulin, consider discontinuing noninsulin agents other than metformin, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-30291106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-30291106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Initial:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Prandial insulin regimens are typically initiated as one daily injection administered before the largest meal; additional mealtime injections may be added based on results of glucose monitoring. In patients with HbA<sub>1c</sub> &lt;8% when prandial insulin is initiated, consider reducing the basal insulin daily dose by 4 units/day <b>or</b> by 10% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ (U-100): </b>4 to 6 units <b>or</b> 10% of the <b>basal</b> insulin dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Dosage adjustment: </i>Note: </b>Individualize dosage adjustments based on patient-specific factors (eg, glucose levels, carbohydrate intake) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>For persistently elevated glucose levels: SUBQ (U-100): </b>Consider intensification of dietary modifications and/or increasing the corresponding mealtime dose(s) by 1 to 2 units <b>or</b> by 10% to 15% every 3 days to achieve glycemic targets while avoiding hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.1'])">Ref</a></span>). <b>Note:</b> More aggressive dose increases (eg, by ≥5 units) may be required in patients already taking &gt;20 units/dose of regular insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>For hypoglycemia: SUBQ (U-100): </b>For unexplained mild to moderate hypoglycemia, consider decreasing the corresponding mealtime dose(s) by 10% to 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>); for hypoglycemia requiring assistance from another person or blood glucose &lt;40 mg/dL, consider decreasing the corresponding mealtime dose(s) by 20% to 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Conversion from other insulin regimens to concentrated U-500 (500 units/mL) regular insulin:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>May be considered in patients requiring a total daily insulin dose &gt;200 units/day. Discontinue all other insulin products prior to initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25813411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25813411'])">Ref</a></span>). Patient should be under the care of a clinician experienced with using concentrated U-500 regular insulin.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Initial:</i> SUBQ (concentrated U-500): </b>Initial dosing depends on proximity to glycemic targets. One strategy is to administer the current total daily insulin dose as concentrated U-500 regular insulin, rounded down to the nearest 5 units, in 2 divided doses (eg, 60% prior to morning meal, 40% prior to evening meal <b>or</b> 50% before morning and evening meals) or 3 divided doses (eg, 40% prior to morning meal and 30% prior to midday and evening meals) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25813411','lexi-content-ref-19211405','lexi-content-ref-Wexler.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25813411','lexi-content-ref-19211405','lexi-content-ref-Wexler.1','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> In patients close to glycemic targets (eg, HbA<sub>1c</sub> ≤8%), consider reducing the initial daily concentrated U-500 regular insulin dose by 10% to 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25813411','lexi-content-ref-19211405','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25813411','lexi-content-ref-19211405','lexi-content-ref-Wexler.1'])">Ref</a></span>); some experts reduce the initial U-500 regular insulin dose by 20% even in patients far from glycemic targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Dosage adjustment:</i> Note: </b>Individualize dosage adjustments based on glucose levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>For persistently elevated glucose levels: SUBQ (concentrated U-500): </b>Increase daily dose by 10% to 20% weekly while avoiding hypoglycemia; in patients receiving 3 injections/day, consider increasing only 2 of the 3 daily doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25813411','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25813411','lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>For hypoglycemia: SUBQ (concentrated U-500): </b>For unexplained mild to moderate hypoglycemia, consider decreasing daily dose by 10% to 30% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-25813411','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-25813411','lexi-content-ref-Wexler.1'])">Ref</a></span>); for severe hypoglycemia requiring assistance from another person or blood glucose &lt;40 mg/dL, consider decreasing daily dose by 20% to 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>For a missed meal: SUBQ (concentrated U-500): </b>Decrease dose by 50% for that meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25813411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25813411'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="87b665ef-68eb-453a-80ad-91aa786100ef">Patients with diabetes receiving enteral feedings</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Patients with diabetes receiving enteral feedings: Note:</b> TDD of insulin is divided into a basal component (intermediate- or long-acting insulin) and nutritional and correctional components (regular insulin or rapid-acting insulins).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nutritional:</i>
<b>SUBQ (U-100):</b> 1 unit of regular insulin per 10 to 15 g of carbohydrate prior to each bolus feeding; in patients receiving continuous feeds, administer every 6 hours based on the amount of carbohydrate administered over each 6-hour period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Correctional: </i>
<b>SUBQ (U-100):</b> Administer correctional insulin as needed prior to each feeding (for bolus feeds) or every 6 hours (for continuous feeds) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>). Dosing is individualized; one example of an empiric correctional dose is 1 to 2 units per 40 to 50 mg/dL above target glucose level; patients with known insulin resistance or who are receiving glucocorticoids may require higher correctional doses (eg, 4 units per 50 mg/dL above target glucose level) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-Magaji.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-Magaji.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="544ea337-a10f-4df4-8f24-3652752931d1">Patients with diabetes receiving parenteral feedings</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Patients with diabetes receiving parenteral feedings:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (U-100; added to TPN solution):</b> 1 unit of regular insulin per 10 g of carbohydrate added to TPN IV solution; adjust dose daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>). One option is to increase the amount of regular insulin added to the TPN by two-thirds of the amount of the correctional insulin used on the previous day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Newton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Newton.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ (U-100):</b> Administer correctional regular insulin every 6 hours as needed for hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>). Dosing is individualized; one example of an empiric correctional dose is 1 to 2 units per 40 to 50 mg/dL above target glucose level; patients with known insulin resistance or who are receiving glucocorticoids may require higher correctional doses (eg, 4 units per 50 mg/dL above target glucose level) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-Magaji.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-Magaji.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="416ede05-90f0-450c-a473-d7b0ea1dad5e">Patients with diabetes undergoing surgery and using an insulin pump</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Patients with diabetes undergoing surgery and using an insulin pump:</b>
<b>SUBQ:</b> For short procedures (eg, &lt;2 hours), continue the usual pump “basal” insulin infusion rate, with or without a temporary 20% to 40% rate reduction, on the morning of the procedure. For long and complex procedures, consider transitioning from the insulin pump to an IV regular insulin infusion perioperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-29162977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-29162977'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81f8f7e2-12a2-41ce-9684-a0869ba7fcf2">Cadaveric organ recovery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cadaveric organ recovery (hormonal resuscitation) (off-label use):</b>
<b>IV (premixed solution or diluted U-100 product for IV infusion):</b> Continuous infusion of 1 unit/hour (minimum dose) to maintain blood glucose of 120 to 180 mg/dL <b>or</b> 20 units as a bolus dose (after an IV bolus of dextrose 25 g) administered to the brain-dead donor who is hemodynamically unstable requiring significant vasopressor support; give concomitantly with levothyroxine or liothyronine (preferred), vasopressin, and methylprednisolone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12605114','lexi-content-ref-12717226','lexi-content-ref-12243491','lexi-content-ref-17488392','lexi-content-ref-12176957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12605114','lexi-content-ref-12717226','lexi-content-ref-12243491','lexi-content-ref-17488392','lexi-content-ref-12176957'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc4e85ce-13fe-4a51-b4ca-644d4bd36693">Diabetic ketoacidosis or hyperosmolar hyperglycemic state</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic ketoacidosis or hyperosmolar hyperglycemic state (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Begin correction of fluid deficits, if present. If serum potassium is &lt;3.3 mEq/L on initial presentation, delay insulin administration until serum potassium reaches ≥3.3 mEq/L. Address other electrolyte abnormalities, as needed, during insulin administration. Administer IV insulin until diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) has resolved. If serum glucose is &lt;250 mg/dL when IV insulin is started, initiate dextrose-containing IV fluids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28924481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28924481'])">Ref</a></span>). An example of a dosing regimen is as follows; refer to institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19564476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (U-100):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Administer continuous infusions using premixed solution or diluted U-100 product for IV infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 0.1 units/kg IV bolus, followed by 0.1 units/kg/<b>hour</b> via IV infusion, <b>or</b> 0.14 units/kg/<b>hour</b> via IV infusion (no bolus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19564476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment:</i> Increase the IV infusion rate (eg, by double) each hour if serum glucose does not decrease by ~50 to 75 mg/dL in the first hour. Once serum glucose approaches 200 to 250 mg/dL (DKA) or 250 to 300 mg/dL (HHS), may decrease IV infusion (eg, to 0.02 to 0.05 units/kg/<b>hour</b>) and administer dextrose-containing IV fluids until DKA or HHS has resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25061324','lexi-content-ref-Hirsch.1','lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25061324','lexi-content-ref-Hirsch.1','lexi-content-ref-19564476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transition from IV to SUBQ insulin:</b> After resolution of the hyperglycemic crisis, may initiate a SUBQ insulin regimen (eg, with basal and prandial insulin); avoid ultra–long-acting basal insulins (eg, degludec, insulin glargine U-300 [300 units/mL]) in this setting due to their long time to reach maximal glycemic effect. Continue the IV insulin infusion for ~1 to 4 hours after the first SUBQ insulin dose to avoid rebound hyperglycemia or ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28372715','lexi-content-ref-Hirsch.1','lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28372715','lexi-content-ref-Hirsch.1','lexi-content-ref-19564476'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70b35ef8-5589-4fcf-8fcb-ab71c5c307ec">Hyperglycemia, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<b>Hyperglycemia, hospitalized patients (off-label use):</b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with persistent hyperglycemia (eg, blood glucose ≥140 to 180 mg/dL for &gt;12 to 24 hours) with or without a history of diabetes; use of institution-specific protocols to achieve glycemic targets and minimize hypoglycemia is encouraged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-23164767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (</b>
<b>premixed solution or diluted U-100 product for IV infusion):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> IV administration of regular insulin is preferred over SUBQ in critically ill patients and may be considered in some perioperative patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-23164767','lexi-content-ref-34605781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-23164767','lexi-content-ref-34605781'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV continuous infusion: Initial: 1 to 4 units per hour, then titrate to achieve target blood glucose (eg, 140 to 180 mg/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-19318384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-19318384'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Transition from IV to SUBQ insulin: </i>Before discontinuation, transition stable ICU patients to a protocol-driven ‘basal-bolus’ insulin regimen, based on insulin infusion history and carbohydrate intake, to maintain glucose levels in target range; avoid ultra–long-acting basal insulins (eg, degludec, insulin glargine U-300 [300 units/mL]) in this setting due to their long time to reach maximal glycemic effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-Hirsch.1','lexi-content-ref-19318384','lexi-content-ref-19636533','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-Hirsch.1','lexi-content-ref-19318384','lexi-content-ref-19636533','lexi-content-ref-23164767'])">Ref</a></span>). <b>Note: </b>Administer initial dose of basal insulin ≥2 to 4 hours before discontinuing IV insulin infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-23164767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>SUBQ administration of regular insulin may be considered in noncritically ill patients or in critically ill patients who have low insulin requirements and do not have conditions affecting absorption (eg, shock, edema) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-23164767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Correctional insulin:</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>For use in addition to scheduled basal and nutritional insulin to achieve glycemic targets; prolonged use of correctional-only (ie, sliding scale) insulin regimens without basal insulin is discouraged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-19454396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ (U-100):</b> Refer to institution-specific protocols; one example of an empiric correctional dose is 1 to 2 units per 40 to 50 mg/dL above target glucose level; dose is typically administered with meals (or bolus feeds) or every 6 hours (if NPO or receiving continuous feeds); patients with known insulin resistance or who are receiving glucocorticoids may require higher correctional doses (eg, 4 units per 50 mg/dL above target glucose level) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-Magaji.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-Magaji.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Nutritional insulin:</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial daily dosage:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Patients not receiving nutritional insulin prior to hospitalization:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Patients eating meals:</i>
<b>SUBQ (U-100):</b> 0.03 to 0.1 units/kg/<b>meal </b>administered with or just after meals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747243','lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747243','lexi-content-ref-22223765'])">Ref</a></span>). <b>Note: </b>Dose is individualized; consider doses at the lower end of this range in older patients and in those with renal impairment; consider doses at the higher end of this range in patients receiving glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22223765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Patients receiving enteral feeds</i>
<i>:</i>
<b> SUBQ (U-100):</b> 1 unit of regular insulin per 10 to 15 g of carbohydrate prior to each bolus feeding; in patients receiving continuous feeds, administer every 6 hours based on the amount of carbohydrate administered over each 6-hour period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Patients receiving nutritional insulin prior to hospitalization: <b>SUBQ (U-100):</b> Continue the prehospitalization nutritional insulin dose; an empiric 20% to 50% dose reduction may be considered in patients with impaired renal function, poor nutritional intake, or admission glucose levels &lt;100 mg/dL; higher doses may be required in patients receiving glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-Inzucchi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-Inzucchi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage adjustment:</i> Adjust daily dose by 10% to 20% every 2 to 3 days to achieve glycemic targets. Consider reducing dosage for glucose levels &lt;100 mg/dL to avoid hypoglycemia; in patients with glucose levels &lt;40 mg/dL, larger dose reductions (eg, by 20% to 40%) may be needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-19454396'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="637f3b98-5df7-446f-8c61-563a0b944ec9">Hyperkalemia, severe/emergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, severe/emergent (off-label use): Note:</b> Use in patients with hyperkalemia-associated ECG changes or other clinical signs consistent with hyperkalemia; <b>or</b> serum potassium &gt;6.5 mEq/L; <b>or </b>serum potassium &gt;5.5 mEq/L, plus significant kidney function impairment and either ongoing tissue breakdown (eg, rhabdomyolysis) or ongoing potassium absorption (eg, substantial GI bleeding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31706619','lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31706619','lexi-content-ref-Mount.1'])">Ref</a></span>). Causes a temporary shift of serum potassium intracellularly. Consider use in combination with IV calcium to stabilize myocardial cell membranes and other methods of decreasing serum potassium and enhancing potassium removal/excretion as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228'])">Ref</a></span>). <b>Safety: </b>Serum glucose monitoring, continuous cardiac monitoring, and serial ECGs are warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mount.1'])">Ref</a></span>). Administration of insulin for the treatment of hyperkalemia has been associated with errors (eg, therapy delays, dosing, wrong routes). Institutions should develop protocols and standard order sets to help reduce errors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Smetzer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Smetzer.1'])">Ref</a></span>). Practice may vary; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (U-100):</b> 10 units given as an IV bolus, along with separate administration of 25 to 50 g dextrose administered over 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2266671','lexi-content-ref-31084947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2266671','lexi-content-ref-31084947'])">Ref</a></span>). After initial dose of dextrose, some experts administer 10% dextrose continuous IV infusion at 50 to 100 mL/hour for ~5 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mount.1','lexi-content-ref-31084947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mount.1','lexi-content-ref-31084947'])">Ref</a></span>). <b>Note:</b> Consider omitting dextrose if blood glucose is ≥250 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31084947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31084947'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Patients with risk factors for hypoglycemia (eg, pretreatment serum glucose &lt;140 mg/dL, kidney impairment, lower body weight): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV (U-100):</b> 5 units given as an IV bolus, along with separate administration of 25 g dextrose administered over 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29553285','lexi-content-ref-28976587','lexi-content-ref-32426734','lexi-content-ref-33993515','lexi-content-ref-26762588']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29553285','lexi-content-ref-28976587','lexi-content-ref-32426734','lexi-content-ref-33993515','lexi-content-ref-26762588'])">Ref</a></span>). After initial dose of dextrose, some experts administer 10% dextrose continuous IV infusion at 50 to 100 mL/hour for ~5 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mount.1','lexi-content-ref-31084947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mount.1','lexi-content-ref-31084947'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration:</b> May repeat dosing every 2 to 4 hours as needed; monitor serum potassium and blood glucose every hour for up to 6 hours after insulin has been administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228','lexi-content-ref-Mount.1','lexi-content-ref-31084947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228','lexi-content-ref-Mount.1','lexi-content-ref-31084947'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991342"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be needed as insulin requirements may be reduced due to changes in insulin clearance or metabolism. The following adjustments have been recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ, IV:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 50 mL/minute: Administer 75% of normal dose and monitor glucose closely.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Administer 50% of normal dose and monitor glucose closely.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Because of a large molecular weight (6,000 daltons), insulin is not significantly removed by hemodialysis; supplemental dose is not necessary</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Because of a large molecular weight (6,000 daltons), insulin is not significantly removed by peritoneal dialysis; supplemental dose is not necessary</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous renal replacement therapy: Administer 75% of normal dose and monitor glucose closely; supplemental dose is not necessary</p></div>
<div class="block doha drugH1Div" id="F50988712"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.</p></div>
<div class="block adr drugH1Div" id="F2104969"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Injection site pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amyloidosis (localized at injection site), hypoglycemia, hypokalemia, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immunogenicity</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site, hypertrophy at injection site, lipoatrophy at injection site, swelling at injection site</p></div>
<div class="block coi drugH1Div" id="F2104968"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to regular insulin or any component of the formulation; during episodes of hypoglycemia.</p></div>
<div class="block war drugH1Div" id="F2105113"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glycemic control: Hyper- or hypoglycemia may result from changes in insulin strength, manufacturer, type, and/or administration method. The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content, timing of meals), changes in the level of physical activity, increased work or exercise without eating, or changes to coadministered medications. Use of long-acting insulin preparations (eg, insulin degludec, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long-standing diabetes, diabetic nerve disease, patients taking beta-blockers, or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe, life-threatening, generalized allergic reactions, including anaphylaxis, may occur. If hypersensitivity reactions occur, discontinue therapy, treat the patient with supportive care and monitor until signs and symptoms resolve.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia, and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with IV insulin use and supplement potassium when necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Type 2 diabetes, hypoglycemia: Closely monitor insulin dose requirement throughout active weight loss with a goal of eliminating antidiabetic therapy or transitioning to agents without hypoglycemic potential; hypoglycemia after gastric bypass, sleeve gastrectomy, and gastric band may occur (Mechanick 2020). Insulin secretion and sensitivity may be partially or completely restored after these procedures (Korner 2009; Peterli 2012). Rates and timing of type 2 diabetes improvement and resolution vary widely by patient. Insulin dose reduction of ≥75% has been suggested after gastric bypass for patients without severe β-cell failure (fasting c-peptide &lt;0.3 nmol/L) (Cruijsen 2014). Avoid the use of bolus insulin injections or dose conservatively with close clinical monitoring in the early phases after surgery.</p>
<p style="text-indent:-2em;margin-left:6em;">– Weight gain: Insulin therapy is preferred if antidiabetic therapy is required during the perioperative period (Mechanick 2019). Evaluate risk versus benefit of long-term postoperative use and consider alternative therapy due to potential for insulin-induced weight gain (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Concurrent use with peroxisome proliferator-activated receptor (PPAR)-gamma agonists, including thiazolidinediones, may cause dose-related fluid retention and lead to or exacerbate heart failure, particularly when used in combination with insulin. If PPAR-gamma agonists are prescribed, monitor for signs and symptoms of heart failure. If heart failure develops, consider PPAR-gamma agonist dosage reduction or therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; increased risk of hypoglycemia. Dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; increased risk of hypoglycemia. Dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients: Prolonged use of a correctional-only (ie, sliding scale) insulin regimen in the inpatient setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, basal insulin use is preferred, with correctional doses (insulin regular or rapid-acting insulin) as needed. In noncritically ill patients with adequate nutritional intake, a combination of basal insulin along with nutritional and correctional components (insulin regular or rapid-acting insulin) is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia. A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Product variation: Human insulin differs from animal-source insulin. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Verify product label prior to administration to prevent medication errors.</p>
<p style="text-indent:-2em;margin-left:4em;">• U-500 regular insulin: <b>U-500 regular insulin is a concentrated insulin formulation which contains 500 units of insulin per mL and is intended for SUBQ administration only; do not administer IV or IM.</b> U-500 regular insulin is generally not recommended for use in an insulin pump but may be used in select patients under the supervision of an experienced provider (AACE [Grunberger 2010]). Prescribe only to patients who require &gt;200 units of insulin per day. Doses from a U-500 regular insulin vial should be drawn up only with a dedicated U-500 insulin syringe. Do not mix or dilute U-500 regular insulin with other insulin formulations. Insulin U-500 also has a delayed onset and longer duration of action compared to regular insulin U-100, and has both prandial and basal properties (ADA 2022). Do not perform dose conversions when using the KwikPen, the dose window shows the number of units to be injected. Do not transfer insulin from the KwikPen to a syringe for administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patient education: Diabetes self-management education is essential to maximize the effectiveness of therapy.</p></div>
<div class="block foc drugH1Div" id="F2104923"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumuLIN R: 100 units/mL (3 mL, 10 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN R: 100 units/mL (10 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN R ReliOn: 100 units/mL (10 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myxredlin: 100 units/100 mL in NaCl 0.9% (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumuLIN R U-500 (CONCENTRATED): 500 units/mL (20 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN R FlexPen: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN R FlexPen ReliOn: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumuLIN R U-500 KwikPen: 500 units/mL (3 mL) [contains metacresol]</p></div>
<div class="block geq drugH1Div" id="F2104963"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F3422171"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (HumuLIN R Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $5.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (HumuLIN R U-500 (CONCENTRATED) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 units/mL (per mL): $89.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Myxredlin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100UT/100ML 0.9% (per mL): $0.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (NovoLIN R Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $5.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (NovoLIN R ReliOn Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $5.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (HumuLIN R U-500 KwikPen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 units/mL (per mL): $114.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (NovoLIN R FlexPen Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $7.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (NovoLIN R FlexPen ReliOn Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $7.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868742"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumuLIN R: 100 units/mL (3 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN GE Toronto: 100 units/mL (10 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myxredlin: 100 units/100 mL in NaCl 0.9% (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLIN GE Toronto Penfill: 100 units/mL (1.5 mL, 3 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HumuLIN R KwikPen: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entuzity Kwikpen: 500 units/mL (3 mL) [contains metacresol]</p></div>
<div class="block admp drugH1Div" id="F52614186"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Do not use if solution is viscous or cloudy; use only if clear and colorless.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: Administer ~30 minutes before meals. Cold injections should be avoided. Administration is usually made into the subcutaneous fat of the thighs, arms, buttocks, or abdomen; rotate injection sites within the same region to avoid lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia. Per the manufacturer, Novolin regular insulin is not recommended for use in external SUBQ insulin infusion pump due to precipitation concerns.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>U-100 regular insulin:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Vial: When mixing U-100 regular insulin with other insulin preparations, regular insulin should be drawn into the syringe first. While not preferred, regular insulin may be infused SUBQ by external insulin pump (eg, when rapid-acting insulin not available) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29999222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29999222'])">Ref</a></span>); however, when used in an external pump, it is not recommended to be diluted with other solutions.</p>
<p style="text-indent:-2em;margin-left:6em;">Prefilled pens: Novolin R FlexPen and Novolin R FlexPen ReliOn are available in a concentration of 100 units/mL. Devices are designed to display the actual insulin units administered (no dosage conversion needed) and will administer up to 60 units per injection in 1-unit increments. Prime the needle before each injection with 2 units of insulin (use a new needle for each injection); see manufacturer's labeling for specific procedure. Once primed, set dial to the appropriate dose, insert needle into clean skin, and activate device by holding the button down; continue to hold the button until the dose dial has returned to 0 units. After the insulin is injected, hold the needle in the skin for ≥6 seconds after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered. Do not rub the area. If dose is &gt;60 units, &gt;1 injection will be required; split dose and administer in multiple injections. Do not mix other insulin formulations with insulin regular contained in a prefilled pen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>U-500 regular insulin</i> (concentrated): Concentrated U-500 regular insulin is indicated only in patients requiring &gt;200 units/day of insulin. Do not dilute or mix U-500 regular insulin.</p>
<p style="text-indent:-2em;margin-left:6em;">Vial: <b>U</b>
<b>-500 regular insulin vials are to be used only in conjunction with a dedicated U-500 insulin syringe; dosage conversion is not required with the U-500 syringe</b>. Only in cases where the U-500 insulin syringe is not available, a U-100 insulin syringe or a tuberculin syringe may be necessary. When using a U-100 syringe or a tuberculin syringe to deliver Humulin R U-500 (from vial), a conversion step is required to ensure the correct amount of Humulin R U-500 is drawn up in the syringe. To avoid dosing errors when using a U-100 insulin syringe, the prescribed dose should be written in actual insulin units and as unit markings on the U-100 insulin syringe (eg, Humulin R U-500 50 units = 10 units on a U-100 insulin syringe). To avoid dosing errors when using a tuberculin syringe, the prescribed dose should be written in actual insulin units and as a volume (eg, Humulin R U-500 50 units = 0.1 mL on a tuberculin syringe).</p>
<p style="text-indent:-2em;margin-left:6em;">Prefilled pen: Do not perform dose conversions when using the KwikPen; the dose window shows the number of units to be injected. The Humulin R KwikPen will administer up to 300 units per injection in 5-unit increments. Prime the needle before each injection with 5 units of insulin (use a new needle for each injection); see manufacturer's labeling for specific procedure. Once primed, set dial to the appropriate dose, insert needle into clean skin, and activate device by holding the button down; continue to hold the button until the dose dial has returned to 0 units. After the insulin is injected, hold the needle in the skin for 5 seconds after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered. Do not rub the area. If dose is &gt;300 units, &gt;1 injection will be required; split dose and administer in multiple injections. Do not transfer KwikPen insulin into a syringe for administration.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: <i>U-100 regular insulin</i>: May be administered IM in selected clinical situations; close monitoring of blood glucose and serum potassium as well as medical supervision is required. <b>Do not administer U-500 regular insulin IM.</b></p>
<p style="text-indent:-2em;margin-left:2em;">IV: <i>U-100 regular insulin</i>: Preferred insulin formulation approved for IV administration; requires close monitoring of blood glucose and serum potassium; appropriate medical supervision. Do not administer U-500 regular insulin or mixtures of insulin formulations intravenously.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV Infusion: <i>U-100 regular insulin: </i>To minimize insulin adsorption to plastic IV tubing: Insulin loss will occur by adsorption to plastic (ie, PVC, polyethylene, polyolefin, polypropylene) IV containers and tubing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Greenwood.1','lexi-content-ref-406784','lexi-content-ref-7020415','lexi-content-ref-24143117','lexi-content-ref-22746979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Greenwood.1','lexi-content-ref-406784','lexi-content-ref-7020415','lexi-content-ref-24143117','lexi-content-ref-22746979'])">Ref</a></span>). Therefore, flush IV tubing with a priming volume of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17037974','lexi-content-ref-23164767','lexi-content-ref-22746979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17037974','lexi-content-ref-23164767','lexi-content-ref-22746979'])">Ref</a></span>). Studies examining this issue in neonates suggest that flushing the IV tubing prior to administration reduces adsorption and provides improved and more predictable insulin delivery; however, the combination of flushing along with preconditioning (waiting a predefined time after flushing the IV line before infusing) provides the greatest reduction in insulin adsorption; wait times for preconditioning varied among studies from 20 to 60 minutes; flush volumes varied and were as high as 20 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9832576','lexi-content-ref-10849219','lexi-content-ref-8176576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9832576','lexi-content-ref-10849219','lexi-content-ref-8176576'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">High-dose insulin therapy (for treating calcium channel blocker or beta-blocker toxicity): <i>U-100 regular insulin:</i> Administer as a continuous IV infusion. Additional precautions should be implemented to ensure accurate infusion pump settings, with particular attention to infusion concentration required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29452919','lexi-content-ref-30141827','lexi-content-ref-34957477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29452919','lexi-content-ref-30141827','lexi-content-ref-34957477'])">Ref</a></span>). Refer to institution-specific protocols where appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">Because of adsorption to plastic IV tubing or infusion bags, the actual amount of insulin being administered could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on the effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SUBQ dosing regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19454396'])">Ref</a></span>); however, the transition to SUBQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy.</p></div>
<div class="block adm drugH1Div" id="F2104992"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ administration:</b> Do not use if solution is viscous or cloudy; use only if clear and colorless. Regular insulin should be administered ~30 minutes before a meal. Cold injections should be avoided. SUBQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites within the same region to avoid lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>U-100 regular insulin:</i> When mixing U-100 regular insulin with other preparations of insulin, regular insulin should be drawn into syringe first.</p>
<p style="text-indent:-2em;margin-left:6em;">FlexPen: Prime the needle before each injection with 2 units of insulin. Once injected, hold the needle in the skin for at least 6 seconds after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>U-500 regular insulin (concentrated):</i> Do not dilute or mix U-500 regular insulin.</p>
<p style="text-indent:-2em;margin-left:6em;">Vials:<b> U-500 regular insulin vials are to be used only in conjunction with a dedicated U-500 insulin syringe; dosage conversion is not required with the U-500 syringe. </b>Only in cases where the U-500 insulin syringe is not available, a U-100 insulin syringe or a tuberculin syringe may be necessary. When using a U-100 syringe or a tuberculin syringe to deliver Humulin R U-500 (from vial), a conversion step is required to ensure the correct amount of Humulin R U-500 is drawn up in the syringe. To avoid dosing errors when using a U-100 insulin syringe, the prescribed dose should be written in actual insulin units and as unit markings on the U-100 insulin syringe (eg, Humulin R U-500 50 units = 10 units on a U-100 insulin syringe). To avoid dosing errors when using a tuberculin syringe, the prescribed dose should be written in actual insulin units and as a volume (eg, Humulin R U-500 50 units = 0.1 mL on a tuberculin syringe).</p>
<p style="text-indent:-2em;margin-left:6em;">Humulin KwikPen (U-500): Do not perform dose conversions when using the KwikPen; the dose window shows the number of units to be injected. The KwikPen dials by 5-unit increments, resulting in delivery of doses in 5-unit increments. Do not transfer KwikPen insulin into a syringe for administration. Prime the needle before each injection with 5 units of insulin. Once the dose is injected, hold the needle in the skin for ~5 seconds after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered.</p>
<p style="text-indent:-2em;margin-left:6em;">Entuzity KwikPen (U-500) [Canadian product]: Do not perform dose conversions when using the KwikPen; the dose window shows the number of units to be injected. The KwikPen dials by 5-unit increments, resulting in delivery of doses in 5-unit increments. Do not transfer KwikPen insulin into a syringe for administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous SUBQ insulin infusion:</i> Novolin regular insulin (U-100) is not recommended for use in external SUBQ insulin infusion pump due to precipitation concerns (manufacturer labeling). Concentrated U-500 regular insulin is generally not recommended for use in an insulin pump but may be used in select patients under the supervision of an experienced provider (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21356638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21356638'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV administration: Do not administer concentrated U-500 regular insulin or mixtures of insulin formulations IV.</b> Do not use if solution is viscous or cloudy; use only if clear and colorless. U-100 regular insulin may be administered IV with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required. <b>Note:</b> A 100 units/100 mL premixed solution is also available for IV infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusions: To minimize insulin adsorption to plastic IV tubing: Insulin loss will occur by adsorption to plastic (ie, PVC, polyethylene, polyolefin, polypropylene) IV containers and tubing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Greenwood.1','lexi-content-ref-406784','lexi-content-ref-7020415','lexi-content-ref-24143117','lexi-content-ref-22746979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Greenwood.1','lexi-content-ref-406784','lexi-content-ref-7020415','lexi-content-ref-24143117','lexi-content-ref-22746979'])">Ref</a></span>). Therefore, flush the IV tubing with a priming infusion of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23164767','lexi-content-ref-22746979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23164767','lexi-content-ref-22746979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">If insulin is required prior to the availability of the insulin infusion, regular insulin should be administered by IV push injection.</p>
<p style="text-indent:-2em;margin-left:4em;">Because of insulin adsorption to plastic IV tubing or infusion bags, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SUBQ dosing regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19454396'])">Ref</a></span>); however, the transition to SUBQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SUBQ basal insulin should be administered ≥2 to 4 hours before discontinuing IV insulin infusion to prevent hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-23164767'])">Ref</a></span>).</p></div>
<div class="block uicn drugH1Div" id="F14472662"><span class="drugH1">Usual Infusion Concentrations: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>IV Infusion:</b> 0.1 unit/mL <b>or</b> 0.5 unit/mL</p></div>
<div class="block uicp drugH1Div" id="F14472661"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 0.1 unit/mL, 0.2 unit/mL, 0.5 unit/mL, or 1 unit/mL.</p></div>
<div class="block sts drugH1Div" id="F2105118"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Humulin R U-100: Store <b>unopened</b> vials under refrigeration between 2°C and 8°C (36°F and 46°F) until expiration date or at room temperature ≤30°C (≤86°F) for 31 days; do not freeze and do not use if the vial has been frozen; keep away from heat and sunlight. Store <b>in-use</b> vials under refrigeration between 2°C and 8°C (36°F and 46°F) or at room temperature ≤30°C (≤86°F) and use within 31 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Humulin R U-500:</p>
<p style="text-indent:-2em;margin-left:4em;">Vials: Store <b>unopened</b> vials under refrigeration between 2°C and 8°C (36°F and 46°F) until expiration date or at room temperature ≤30°C (≤86°F) for 40 days; do not shake; protect from heat and light; do not freeze and do not use if the vial has been frozen. Store <b>in-use </b>vials under refrigeration between 2°C and 8°C (36°F and 46°F) or at room temperature ≤30°C (≤86°F) and use within 40 days.</p>
<p style="text-indent:-2em;margin-left:4em;">KwikPen: Store <b>unopened</b> prefilled pens under refrigeration between 2°C and 8°C (36°F and 46°F) until expiration date or at room temperature ≤30°C (≤86°F) for 28 days; protect from heat and light; do not freeze and do not use if the pen has been frozen. Store <b>in-use</b> prefilled pens at room temperature ≤30°C (≤86°F) and use within 28 days; do not refrigerate.</p>
<p style="text-indent:-2em;margin-left:2em;">Myxredlin: Store at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze or shake. May be stored at room temperature (&lt;25°C [&lt;77°F]) for ≤30 days; do not return to refrigerator once stored at room temperature; discard after 30 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Novolin R:</p>
<p style="text-indent:-2em;margin-left:4em;">Vials: Store <b>unopened</b> vials under refrigeration between 2°C and 8°C (36°F and 46°F) until expiration date or at room temperature ≤25°C (≤77°F) for 42 days; do not freeze; keep away from heat and sunlight. Store <b>in-use</b> vials at room temperature ≤25°C (≤77°F) and use within 42 days; do not refrigerate.</p>
<p style="text-indent:-2em;margin-left:4em;">FlexPen: Store <b>unopened</b> prefilled pens under refrigeration between 2°C and 8°C (36°F and 46°F) until expiration date or at room temperature ≤30°C (≤86°F) for 28 days; do not use if frozen; keep away from heat and light. Store <b>in-use</b> prefilled pens at room temperature ≤30°C (≤86°F) and use within 28 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Canadian labeling (not in US labeling): All products: Store <b>unopened</b> vials, cartridges, and prefilled pens under refrigeration between 2°C and 8°C (36°F and 46°F) until expiration date; do not freeze; keep away from heat and sunlight. Store <b>in-use</b> Humulin vials, cartridges, and prefilled pens at room temperature &lt;25°C (&lt;77°F) and use within 4 weeks. Store <b>in-use</b> Novolin GE vials, cartridges, and prefilled pens at room temperature &lt;25°C (&lt;77°F) for vials or &lt;30°C (&lt;86°F) for prefilled pens/cartridges and use within 1 month; do not refrigerate. Store <b>in-use</b> Entuzity KwikPen prefilled pens at room temperature ≤30°C (≤86°F) and use within 4 weeks; do not refrigerate.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Diluted solution for SUBQ administration:</b>
<i>Humulin R U-100:</i> Diluted insulin solution may be stored at 30°C (86°F) for ≤14 days or at 5°C (41°F) for ≤28 days.</p>
<p style="text-indent:-2em;margin-left:4em;">According to the manufacturer, do not store diluted insulin in a plastic syringe; store unused sterile diluent at room temperature; once in use, the sterile diluent vial should be used within 28 days (data on file [Eli Lilly 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>For IV infusion: </b>
<b>Note:</b> A 100 units/100 mL premixed solution is also available for IV infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Humulin R U-100:</i> Stable for 48 hours at room temperature or for 48 hours under refrigeration followed by 48 hours at room temperature.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Novolin R:</i> Stable for 24 hours at room temperature</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> After dilution of 100 units of regular human insulin (product not specified) in 100 mL of 0.9% NaCl (PVC bag), the solution is stable under refrigeration between 2°C and 8°C (36°F to 46°F) for ≤336 hours (Rocchio 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">After dilution of 800 units of regular insulin (8 mL of a 100 units/mL solution) in 42 mL of 0.9% NaCl (PVC bag) to a final concentration of 16 units/mL, the solution is stable under refrigeration at 4°C (39°F) or at room temperature at 25°C (77°F) for 14 days (Laskey 2016).</p></div>
<div class="block usep drugH1Div" id="F53570005"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Improvement of glycemic control in patients with diabetes mellitus (FDA approved in pediatric patients [age not specified] and adults); has also been used for treatment of diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), treatment of hyperkalemia (used in combination with glucose to cause intracellular shift of potassium and lower serum potassium levels), and treatment of calcium channel blocker or beta-blocker toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Concentrated U-500 regular insulin is indicated only in patients requiring &gt;200 units/day of insulin.</p></div>
<div class="block mst drugH1Div" id="F2104961"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">HumuLIN R may be confused with HumaLOG, Humira, HumuLIN 70/30, HumuLIN N, NovoLIN 70/30, NovoLIN R, NovoLOG</p>
<p style="text-indent:2em;">HumuLIN R U-500 may be confused with Humulin R U-100</p>
<p style="text-indent:-2em;margin-left:4em;">NovoLIN R may be confused with HumuLIN R, NovoLIN 70/30, NovoLIN N, NovoLOG</p>
<p style="text-indent:-2em;margin-left:4em;">Insulin may be confused with influenza virus vaccine. Medication errors have occurred when insulin was inadvertently administered instead of influenza virus vaccine. These products are refrigerated and may be stored in close proximity to each other.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (with special emphasis on U-500 insulin) among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b>
<i>Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.</i></b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Insulin (short- or rapid-acting insulin products used for sliding scale) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to higher risk of hypoglycemia associated with sliding scale insulin without improvements in hyperglycemia, regardless of care setting. Avoid insulin regimens that only use short- or rapid-acting insulins dosed based on current blood glucose levels in the absence of basal or long-acting insulin; recommendation does not apply to regimens containing basal or long-acting insulin (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Concentrated solutions (eg, U-500) should not be available in patient care areas. U-500 regular insulin should be stored, dispensed, and administered separately from U-100 regular insulin. U-500 insulin vials are to be used in conjunction only with a dedicated U-500 insulin syringe. Though no longer recommended by the manufacturer, in cases where the U-500 insulin syringe is not available, a U-100 insulin syringe or a tuberculin syringe may be used (<b>conversion step required to ensure correct dose is drawn up</b>). For patients who receive U-500 insulin in the hospital setting, highlighting the strength prominently on the patient's medical chart and medication record may help to reduce dispensing errors. For patients being discharged from the hospital and/or in the outpatient setting, a U-500 insulin syringe is available by prescription only and should be prescribed/dispensed in conjunction with U-500 insulin vials.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F2104975"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2104974"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: Consider reducing the liraglutide dose if coadministered with insulin. Prescribing information for the Saxenda brand of liraglutide recommends a dose decrease of 50%. Monitor blood glucose for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs and symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F2104991"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>
<div class="block rep_considerations drugH1Div" id="F53325054"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients diagnosed with diabetes who wish to conceive should use adequate contraception until glycemic control is achieved (ADA 2022). Rapid acting insulin analogs are preferred over short acting regular insulin in patients planning to become pregnant (Blumer 2013).</p></div>
<div class="block pri drugH1Div" id="F2105111"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Exogenous insulin bound to anti-insulin antibodies can be detected in cord blood (Menon 1990).</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2022; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, insulin requirements tend to increase as pregnancy progresses, requiring frequent monitoring and dosage adjustments. Following delivery, insulin requirements decrease rapidly (ACOG 201 2018; ADA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Insulin is the preferred treatment of type 1 and type 2 diabetes mellitus in pregnancy, as well as gestational diabetes mellitus when pharmacologic therapy is needed (ACOG 190 2018; ACOG 201 2018; ADA 2022). Rapid acting insulin analogs are preferred over short acting regular insulin when treatment is needed during pregnancy due to improved outcomes and increased compliance (ACOG 198 2018; ACOG 201 2018; Blumer 2013). Regular insulin is used intravenously for glycemic control during labor.</p></div>
<div class="block mopp drugH1Div" id="F53570004"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Diabetes: Serum glucose, electrolytes, HbA<sub>1c</sub> (every 3 months; if patient is stable and meeting treatment goals, may only need twice-yearly testing; patients not stable on intensive therapy [eg, pregnancy] may need more frequent testing) (ADA 2020), renal function (at diagnosis and at least annually) (ADA [Chiang 2014]), hepatic function.</p>
<p style="text-indent:-2em;margin-left:4em;">Diabetic ketoacidosis/hyperosmolar hyperglycemic state: Vital signs, arterial blood gases (initial), venous pH, CBC with differential, urinalysis, serum glucose, BUN, creatinine, electrolytes, calcium, magnesium, phosphate, anion gap, fluid status, blood β-hydroxybutyrate (BOHB) concentration; neurological observations; mental status (ISPAD [Wolfsdorf 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia, neonatal: Monitor serum glucose 30 to 60 minutes after intermittent IV dose, initiation of continuous infusion, or rate change (Eichenwald 2017; Hemachandra 1999); must be closely monitored to avoid hypoglycemia and/or hypokalemia. Consult individual institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">Hyperkalemia: Serum potassium and glucose must be closely monitored to avoid hypoglycemia and/or hypokalemia.</p></div>
<div class="block rerp drugH1Div" id="F53569437"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Plasma Blood Glucose and HbA<sub>1c</sub> Goals for Diabetes Patients: Note:</b> Postprandial blood glucose should be measured when there is a discrepancy between preprandial blood glucose concentrations and HbA<sub>1c</sub> values and to help assess glycemia for patients who receive basal/bolus or pump regimens. It is usually drawn 1 to 2 hours after starting a meal and is considered to be the "peak."</p>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Blood glucose:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Type 1 diabetes:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Capillary glucose measurement: 70 to 180 mg/dL (SI: 3.9 to 10 mmol/L); tighter fasting target (ie, 70 to 144 mg/dL [SI: 3.9 to 8 mmol/L]) is recommended to attain HbA<sub>1c</sub> goals (ISPAD [de Bock 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Type 2 diabetes: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Fasting plasma glucose: 70 to 110 mg/dL (SI: 3.9 to 6.1 mmol/L) (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:8em;">Postprandial glucose: 70 to 140 mg/dL (SI: 3.9 to 7.8 mmol/L) (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">HbA<sub>1c</sub>: &lt;7%; target should be individualized; a more stringent goal (&lt;6.5%) may be reasonable if it can be achieved without significant hypoglycemia; lower targets may also be recommended when using insulin pumps and/or continuous glucose monitoring and during the "honeymoon" phase; less aggressive goals (&lt;7.5% or &lt;8%) may be appropriate in patients who cannot articulate symptoms of hypoglycemia, cannot check glucose frequently, have a history of severe hypoglycemia, have extensive comorbid conditions, or lack access to analog insulins, advanced insulin delivery technology, or continuous glucose monitoring (ADA 2023; ISPAD [de Bock 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">Surgical patients (ISPAD [Kapellen 2022]):</p>
<p style="text-indent:-2em;margin-left:6em;">Intraoperative: 90 to 180 mg/dL (SI: 5 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:6em;">ICU, postsurgery: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L).</p></div>
<div class="block pha drugH1Div" id="F2104981"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>
<p style="text-indent:-2em;margin-left:2em;">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Insulin stimulates lipoprotein lipase synthesis and activity; this results in hydrolysis of triglycerides into free fatty acids and storage of free fatty acids in adipocytes, thereby reducing circulating triglyceride levels (Rawla 2018; Sadur 1982; Song 2019). In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>
<p style="text-indent:-2em;margin-left:2em;">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Regular insulin has an identical structure to that of native human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin regular is a short-acting insulin analog.</p>
<p style="text-indent:-2em;margin-left:2em;">The benefit of hyperinsulinemia-euglycemic therapy (HIET) in patients experiencing toxicity secondary to a calcium channel blocker (CCB) or beta blocker is not fully understood. It is hypothesized HIET improves myocyte glucose uptake and utilization; insulin may also act directly as a concentration-dependent inotrope. Exogenous insulin administration may help to overcome the hypoinsulinemia caused by CCB-induced blockage of L-type calcium channels in pancreatic beta cells (Krenz 2018).</p></div>
<div class="block phk drugH1Div" id="F2104982"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration (absorption and onset of action are more rapid after deeper IM injections than after SUBQ), site of injection (onset and duration are progressively slower with SUBQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature. Insulin regular is available in a U-100 (100 units/mL) formulation and a concentrated U-500 (500 units/mL) formulation, which have different pharmacodynamic/kinetic profiles.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>U-100 formulation:</b> IV: ~10 to 21 minutes; SUBQ: ~30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>U-500 formulation:</b> SUBQ: &lt;15 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peak effect:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>U-100 formulation:</b> IV infusion: ~5 hours; SUBQ: 1.5 to 3.5 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>U-500 formulation:</b> SUBQ: 4 to 8 hours (dose dependent).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>U-100 formulation:</b> IV infusion: 1.5 hours after stopping infusion; SUBQ: ~8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>U-500 formulation:</b> SUBQ: 13 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: <b>U-100 formulation: </b>IV: 0.32 to 0.67 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: <b>U-100 formulation:</b> SUBQ: 48% to 89%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>U-100 formulation: </b>IV: ~0.3 to 1 hour (dose dependent); SUBQ: 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>U-500 formulation: </b>SUBQ: 4.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>U-100 formulation:</b> SUBQ: 0.5 to 2.5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>U-500 formulation: </b>SUBQ: 0.5 to 8 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038885"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin regular | Jusline R</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin r | Insulina Densulin R | Insulina Humulin R | Insuman r | Novolin r</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Huminsulin normal | Insulin hm actrapid | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Humulin r</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Ansulin R | Diasulin n | Diasulin r | Humulin r | Insulet n | Insulet r | Insulin actrapid hm | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humuline regular | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Insulet rapide | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Humulin r | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bahiafarma insulina humana r | Biohulin regular | Humulin r | Insuman r | Insunorm n | Insunorm r | Novolin r | Wosulin r</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Insuman rapid</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin r | Insuman</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Biosynthetic Human Insulin | Gan shu lin r | Humulin r | Novolin r</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Gansulin r | Humulin c | Humulin r | Insugen r | Insulex r | Insuman r</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Humulin r | Insulin-HM R | Insuman rapid | Velosulin HM</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Huma ject normal | Huminsulin normal | Humulin normal | Insulin B. Braun ratiopharm rapid | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Humulin regular | Insuman r | Novolin r | Recomulin r</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humulin r | Insuman r | Novolin r</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Humaject R | Humulin r | Insuman rapid | Isuhuman rapid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin regular | Insulin h r | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid innolet | Humaplus regular | Humulina regular</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Actapid | Biosynthetic Human Insulin | Jusline R</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humulin regular | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Humulin regular | Insuman rapid | Umuline rapide | Velosuline hm</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humulin s | Insuman rapid | Pur in Neutral | Velosulin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humulin regular | Insulin actrapid hm | Insuman rapid | Velosulin HM</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin r</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humulin r | Ins actrapid hm | Insulin actrapid hm(ge) | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Humulin r | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humulin r | Humulin s | Insuman</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humulin r</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Humaject R | Human actrapid | Human Insunorm | Human monosulin | Human rapidica | Human-fastact | Humarap | Huminsulin-r | Insugen r | Insuman rapid | Recosulin-r | Wosulin r</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Bio insulin r | Humulin r | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Gensulin r | Humulin r</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Actrapid human | Humacart r | Humulin r | Innolet r | Novolin r | Velosulin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humodar c25 | Humulin r | Jusline R</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humaject R | Humulin r | Novolet r | Novolin r | Velosulin Human</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Humulin regular</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humulin regular | Insuman rapid | Velosulin HM</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Biogulin | Humulin r | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humaject Regular | Humuline regular | Velosuline hm</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Biogulin | Humulin r | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Insulet r | Insulet rapide | Umuline rapide</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Humulin r | Insulex r | Insuman r | Novolin r | Wozulim r</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid flexpen | Actrapid hm | Humulin r</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humuline regular | Inpremzia | Insuman rapid | Velosulin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | H-tronin | Humulin r | Humulin regular | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humulin r</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin c | Humulin r | Insuman r</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Glysolin r | Humulin r | Insulyf r | Insuman rapid | Jusline R | Wosulin r</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Dongsulin R | Humulin regular | Innogen R | Insuget R | Insuman rapid | Zansulin regular</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Gensulin r | Humulin r | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Humulin r | Myxredlin | Novolin r | Relion/Novolin R | Velosulin rdna br</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Humulin regular | Insulina actrapid hm | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin r | Insubest r | Insuman r | Sulina r</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid Penfill | Insuman Rapid</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Humulin r | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Berlinsulin h normal | Biogulin | Biosulin r | Gensulin r | Humodar r | Humulin r | Humulin regular | Ins actrapid hm | Ins actrapid nm | Insuman rapid | Insuman rapid gt | Rosinsulin p | Wozulim r</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin regular</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Insuman rapid | Insuman Rapid SoloStar</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Humulin r</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin r</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin r | Insulin-HM R | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Biosulin r | Gensulin r | Humulin r | Winsulin r</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Insuline actrapid hm | Insuman rapid | Jusline R</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Humulin regular | Insulin Protaphan HM</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin r | Insulin Regular hm | Velosulin | Velosulin HM</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Actrapid hm | Gensulin r | Humulin regular | Insular active | Insuman rapid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Biosulin r | Gensulin r | Humulin regular | Insugen r | Insuman rapid | Wosulin r</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Actrapid hm | Humulin r | Insubest r | Insuman r | Wosulin r</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Humulin c | Humulin r | Insulex r | Insuman r</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Actrapid | Biosulin r | Humaject R | Humulin r</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2266671">
<a name="2266671"></a>Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. <i>Kidney Int</i>. 1990;38(5):869-872. doi:10.1038/ki.1990.284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/2266671/pubmed" id="2266671" target="_blank">2266671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2023">
<a name="ADA.2023"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;45(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed February 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2020">
<a name="ADA.2020"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2020. <i>Diabetes Care</i>. 2020;43(suppl 1):S1-S212. https://care.diabetesjournals.org/content/43/Supplement_1. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2021">
<a name="ADA.2021"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2022.<i> Diabetes Care.</i> 2022;45(suppl 1):S1-S255. https://diabetesjournals.org/care/issue/45/Supplement_1. Accessed September 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747245">
<a name="14747245"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. <i>Diabetes Care.</i> 2004;27(2):596-601.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/14747245/pubmed" id="14747245" target="_blank">14747245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29608329">
<a name="29608329"></a>Anderson PO. Treating diabetes during breastfeeding. <i>Breastfeed Med</i>. 2018;13(4):237-239. doi:10.1089/bfm.2018.0036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/29608329/pubmed" id="29608329" target="_blank">29608329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in <i>J Clin Endocrinol Metab</i>. 2015;100(5):2135-2136]. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi:10.1210/jc.2014-3415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30425094">
<a name="30425094"></a>Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2018;41(12):2648-2668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/30425094/pubmed" id="30425094" target="_blank">30425094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472948">
<a name="26472948"></a>Beck JK, Cogen FR. Outpatient management of pediatric type 1 diabetes. <i>J Pediatr Pharmacol Ther</i>. 2015;20(5):344-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/26472948/pubmed" id="26472948" target="_blank">26472948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28427304">
<a name="28427304"></a>Bergen PM, Kruger DF, Taylor AD, et al. Translating U-500R randomized clinical trial evidence to the practice setting: a diabetes educator/expert prescriber team approach. <i>Diabetes Educ.</i> 2017;43(3):311-323. doi:10.1177/0145721717701579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/28427304/pubmed" id="28427304" target="_blank">28427304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11546970">
<a name="11546970"></a>Brown G, Dodek P. Intravenous insulin nomogram improves blood glucose control in the critically ill. <i>Crit Care Med.</i> 2001;29(9):1714-1719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/11546970/pubmed" id="11546970" target="_blank">11546970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29553285">
<a name="29553285"></a>Brown K Jr, Setji TL, Hale SL, et al. Assessing the impact of an order panel utilizing weight-based insulin and standardized monitoring of blood glucose for patients with hyperkalemia. <i>Am J Med Qual</i>. 2018;33(6):598-603. doi:10.1177/1062860618764610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/29553285/pubmed" id="29553285" target="_blank">29553285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18184958">
<a name="18184958"></a>Brunkhorst FM, Engel C, Bloos F, et al. Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis. <i>N Engl J Med.</i> 2008;358(2):125-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/18184958/pubmed" id="18184958" target="_blank">18184958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cameron.1">
<a name="Cameron.1"></a>Cameron P, Jelinek G, Everitt I, et al. <i>Textbook of Paediatric Emergency Medicine</i>. 2nd ed. Churchill Livingstone Elsevier; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention website. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed March 18, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935775">
<a name="24935775"></a>Chiang JL, Kirkman MS, Laffel LM, Peters AL; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. <i>Diabetes Care</i>. 2014;37(7):2034-2054.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/24935775/pubmed" id="24935775" target="_blank">24935775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706619">
<a name="31706619"></a>Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/31706619/pubmed" id="31706619" target="_blank">31706619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747243">
<a name="14747243"></a>Clement S, Braithwaite SS, Magee MF, et al; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. <i>Diabetes Care</i>. 2004;27(2):553-91. doi:10.2337/diacare.27.2.553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/14747243/pubmed" id="14747243" target="_blank">14747243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cloherty.1">
<a name="Cloherty.1"></a>Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Lippincott Williams &amp; Wilkins; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29452919">
<a name="29452919"></a>Cole JB, Arens AM, Laes JR, et al. High dose insulin for beta-blocker and calcium channel-blocker poisoning. <i>Am J Emerg Med</i>. 2018;36(10):1817-1824. doi:10.1016/j.ajem.2018.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/29452919/pubmed" id="29452919" target="_blank">29452919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23359574">
<a name="23359574"></a>Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, et al; American Academy of Pediatrics. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. <i>Pediatrics</i>. 2013;131(2):364-382. doi:10.1542/peds.2012-3494<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/23359574/pubmed" id="23359574" target="_blank">23359574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24829176">
<a name="24829176"></a>Cruijsen M, Koehestani P, Huttjes S, Leenders K, Janssen I, de Boer H. Perioperative glycaemic control in insulin-treated type 2 diabetes patients undergoing gastric bypass surgery. <i>Neth J Med</i>. 2014;72(4):202-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/24829176/pubmed" id="24829176" target="_blank">24829176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29999222">
<a name="29999222"></a>Danne T, Phillip M, Buckingham B, et al. ISPAD clinical practice consensus guidelines 2018: insulin treatment in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):115-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/29999222/pubmed" id="29999222" target="_blank">29999222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537523">
<a name="36537523"></a>de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1270-1276. doi:10.1111/pedi.13455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/36537523/pubmed" id="36537523" target="_blank">36537523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058221">
<a name="30058221"></a>DiMeglio LA, Acerini CL, Codner E, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):105-114. doi:10.1111/pedi.12737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/30058221/pubmed" id="30058221" target="_blank">30058221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC. <i>Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eli.1">
<a name="Eli.1"></a>Eli Lilly and Company. Case Number 0525124 [written communication]. Indianapolis, IN: Eli Lilly and Company; March 1, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21563902">
<a name="21563902"></a>Engebretsen KM, Kaczmarek KM, Morgan J, et al. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. <i>Clin Toxicol (Phila)</i>. 2011;49(4):277-283. doi:10.3109/15563650.2011.582471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/21563902/pubmed" id="21563902" target="_blank">21563902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Entuzity.1">
<a name="Entuzity.1"></a>Entuzity Kwikpen (insulin injection, human biosynthetic) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28372715">
<a name="28372715"></a>Fayfman M, Pasquel FJ, Umpierrez GE. Management of hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. <i>Med Clin North Am</i>. 2017;101(3):587-606. doi:10.1016/j.mcna.2016.12.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/28372715/pubmed" id="28372715" target="_blank">28372715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation.</i> 2010;122(18)(suppl 3):640-656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fuhrman.1">
<a name="Fuhrman.1"></a>Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9832576">
<a name="9832576"></a>Fuloria M, Friedberg MA, DuRant RH, Aschner JL. Effect of flow rate and insulin priming on the recovery of insulin from microbore infusion tubing. <i>Pediatrics</i>. 1998;102(6):1401-1406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/9832576/pubmed" id="9832576" target="_blank">9832576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32931166">
<a name="32931166"></a>Gianchandani RY, Iyengar JL, Butler SO, et al. Inpatient diabetes guideline for adult non-critically ill patients [Internet]. <i>Michigan Medicine Clinical Care Guidelines</i>. Michigan Medicine, University of Michigan; 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/32931166/pubmed" id="32931166" target="_blank">32931166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17037974">
<a name="17037974"></a>Goldberg PA, Kedves A, Walter K, Groszmann A, Belous A, Inzucchi SE. "Waste not, want not": determining the optimal priming volume for intravenous insulin infusions. <i>Diabetes Technol Ther</i>. 2006;8(5):598-601.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/17037974/pubmed" id="17037974" target="_blank">17037974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25061324">
<a name="25061324"></a>Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. <i>Diabetes Metab Syndr Obes</i>. 2014;7:255-264. doi:10.2147/DMSO.S50516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/25061324/pubmed" id="25061324" target="_blank">25061324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Greenwood.1">
<a name="Greenwood.1"></a>Greenwood BC, Chesnick MA, Szumita PM, Belisle C, Cotugno M. Stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. <i>Hosp Pharm</i>. 2012;47(5):367-370.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21356638">
<a name="21356638"></a>Grunberger G, Bailey TS, Cohen AJ, et al; AACE Insulin Pump Management Task Force. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management.<i> Endocr Pract</i>. 2010;16(5):746-762. doi:10.4158/EP.16.5.746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/21356638/pubmed" id="21356638" target="_blank">21356638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10966679">
<a name="10966679"></a>Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10: pediatric advanced life support (PALS). The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. <i>Circulation</i>. 2000;102(8)(suppl):I291-I342.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/10966679/pubmed" id="10966679" target="_blank">10966679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Handelsman.1">
<a name="Handelsman.1"></a>Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. <i>Endocr Pract</i>. 2015;21(suppl 1):1-87. doi:10.4158/EP15672.GL. https://journals.aace.com/doi/pdf/10.4158/EP15672.GLSUPPL. Accessed April 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hemachandra.1">
<a name="Hemachandra.1"></a>Hemachandra AH, Cowett RM. Neonatal hyperglycemia. <i>Pediatrics in Review</i>. 1999;20(7):e16-e24.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10849219">
<a name="10849219"></a>Hewson M, Nawadra V, Oliver J, Odgers C, Plummer J, Simmer K. Insulin infusions in the neonatal unit: delivery variation due to adsorption. <i>J Paediatr Child Health</i>. 2000;36(3):216-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/10849219/pubmed" id="10849219" target="_blank">10849219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation.</i> 2011;124(23):2610-2642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.1">
<a name="Hirsch.1"></a>Hirsch IB, Emmett M. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed May 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-406784">
<a name="406784"></a>Hirsch JI, Fratkin MJ, Wood JH, Thomas RB. Clinical significance of insulin adsorption by polyvinyl chloride infusion systems. <i>Am J Hosp Pharm</i>. 1977;34(6):583-588.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/406784/pubmed" id="406784" target="_blank">406784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7020415">
<a name="7020415"></a>Hirsch JI, Wood JH, Thomas RB. Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. <i>Am J Hosp Pharm</i>. 1981;38(7):995-997.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/7020415/pubmed" id="7020415" target="_blank">7020415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25813411">
<a name="25813411"></a>Hood RC, Arakaki RF, Wysham C, Li YG, Settles JA, Jackson JA. Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: a randomized, titration-to- target clinical trial.<i> Endocr Pract. </i>2015;21(7):782-793. doi:10.4158/EP15612.OR<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/25813411/pubmed" id="25813411" target="_blank">25813411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8359096">
<a name="8359096"></a>Hopkins DF, Cotton SJ, Williams G. Effective Treatment of Insulin-Induced Edema Using Ephedrine. <i>Diabetes Care.</i> 1993;16(7):1026-1028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/8359096/pubmed" id="8359096" target="_blank">8359096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Humulin.3">
<a name="Humulin.3"></a>Humulin R (insulin regular) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Humulin.2">
<a name="Humulin.2"></a>Humulin R, Humulin N, and Humulin 30/70 (insulin isophane, human biosynthetic [rDNA origin]) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Humulin.1">
<a name="Humulin.1"></a>Humulin R U-500 (insulin regular concentrate) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network. Standard Concentrations of Neonatal Drug Infusions. 2011. https://www.ismp.org/Tools/PediatricConcentrations.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Inzucchi.1">
<a name="Inzucchi.1"></a>Inzucchi SE. Diabetes facts and guidelines. <a href="https://medicine.yale.edu/intmed/drc/diabetescenter/living/50135_Yale%20National%20F_102165_284_13584_v1.pdf" target="_blank">https://medicine.yale.edu/intmed/drc/diabetescenter/living/50135_Yale%20National%20F_102165_284_13584_v1.pdf</a>. Published 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23164767">
<a name="23164767"></a>Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. <i>Crit Care Med.</i> 2012;40(12):3251-3276. doi:10.1097/CCM.0b013e3182653269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/23164767/pubmed" id="23164767" target="_blank">23164767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30039617">
<a name="30039617"></a>Jefferies C, Rhodes E, Rachmiel M, et al. ISPAD clinical practice consensus guidelines 2018: management of children and adolescents with diabetes requiring surgery [published correction appears in <i>Pediatr Diabetes</i>. 2019;20(1):137]. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):227-236. doi:10.1111/pedi.12733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/30039617/pubmed" id="30039617" target="_blank">30039617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-JCAHO.1">
<a name="JCAHO.1"></a>Joint Commission on Accreditation of Healthcare Organizations. 2005 National Patient Safety Goals. http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/05_npsgs.htm
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537521">
<a name="36537521"></a>Kapellen T, Agwu JC, Martin L, et al. ISPAD clinical practice consensus guidelines 2022: management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2022;23(8):1468-1477. doi:10.1111/pedi.13446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/36537521/pubmed" id="36537521" target="_blank">36537521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) diabetes work group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23106132">
<a name="23106132"></a>Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in Older Adults: A Consensus Report. <i>J Am Geriatr Soc.</i> 2012. doi:10.1111/jgs.12035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/23106132/pubmed" id="23106132" target="_blank">23106132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19564476">
<a name="19564476"></a>Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. <i>Diabetes Care.</i> 2009;32(7):1335-1343. doi:10.2337/dc09-9032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/19564476/pubmed" id="19564476" target="_blank">19564476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14693938">
<a name="14693938"></a>Kitabchi AE, Umpierrez GE, Murphy MB, et al. Hyperglycemic Crises in Diabetes. <i>Diabetes Care.</i> 2004;27(suppl 1):94-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/14693938/pubmed" id="14693938" target="_blank">14693938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18 Suppl 3):S876-S908. doi:10.1161/CIRCULATIONAHA.110.971101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi:10.1038/ijo.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30141827">
<a name="30141827"></a>Krenz JR, Kaakeh Y. An Overview of hyperinsulinemic-euglycemic therapy in calcium channel blocker and β-blocker overdose. <i>Pharmacotherapy</i>. 2018;38(11):1130-1142. doi:10.1002/phar.2177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/30141827/pubmed" id="30141827" target="_blank">30141827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412709">
<a name="30412709"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol.</i> 2018. pii: S0735-1097(18)38985-X. doi:10.1016/j.jacc.2018.10.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/30412709/pubmed" id="30412709" target="_blank">30412709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19211405">
<a name="19211405"></a>Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? <i>Endocr Pract</i>. 2009;15(1):71-79. doi:10.4158/EP.15.1.71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/19211405/pubmed" id="19211405" target="_blank">19211405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28976587">
<a name="28976587"></a>LaRue HA, Peksa GD, Shah SC. A comparison of insulin doses for the treatment of hyperkalemia in patients with renal insufficiency. <i>Pharmacotherapy</i>. 2017;37(12):1516-1522. doi:10.1002/phar.2038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/28976587/pubmed" id="28976587" target="_blank">28976587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432286">
<a name="27432286"></a>Laskey D, Vadlapatla R, Hart K. Stability of high-dose insulin in normal saline bags for treatment of calcium channel blocker and beta blocker overdose. <i>Clin Toxicol (Phila).</i> 2016;54(9):829-832. doi:10.1080/15563650.2016.1209766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/27432286/pubmed" id="27432286" target="_blank">27432286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9040630">
<a name="9040630"></a>Lazar HL, Philippides G, Fitzgerald C, et al. Glucose-Insulin-Potassium Solutions Enhance Recovery After Urgent Coronary Artery Bypass Grafting. <i>J Thorac Cardiovasc Surg.</i> 1997;113(2):354-360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/9040630/pubmed" id="9040630" target="_blank">9040630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21181208">
<a name="21181208"></a>Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. <i>Pediatr Nephrol</i>. 2011;26(3):377-384.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/21181208/pubmed" id="21181208" target="_blank">21181208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29162977">
<a name="29162977"></a>Leung V, Ragbir-Toolsie K. Perioperative management of patients with diabetes. <i>Health Serv Insights</i>. 2017;10:1178632917735075. doi:10.1177/1178632917735075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/29162977/pubmed" id="29162977" target="_blank">29162977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28604935">
<a name="28604935"></a>Lipska KJ, Hirsch IB, Riddle MC. Human insulin for type 2 diabetes: an effective, less-expensive option. <i>JAMA.</i> 2017;318(1):23-24. doi:10.1001/jama.2017.6939<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/28604935/pubmed" id="28604935" target="_blank">28604935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Magaji.1">
<a name="Magaji.1"></a>Magaji V, Johnston JM. Inpatient management of hyperglycemia and diabetes. <i>Clinical Diabetes</i>. 2011;29(1):3-9. doi:10.2337/diaclin.29.1.3</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16452564">
<a name="16452564"></a>Malhotra A. Intensive Insulin in Intensive Care. <i>N Engl J Med.</i> 2006;354(5):516-518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/16452564/pubmed" id="16452564" target="_blank">16452564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9169397">
<a name="9169397"></a>Malmberg K. Prospective Randomised Study of Intensive Insulin Treatment on Long Term Survival After Acute Myocardial Infarction in Patients With Diabetes Mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. <i>BMJ. </i>1997;314(7093):1512-1515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/9169397/pubmed" id="9169397" target="_blank">9169397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1986079">
<a name="1986079"></a>Malone TA. Glucose and Insulin Versus Cation-Exchange Resin for the Treatment of Hyperkalemia in Very Low Birth Weight Infants. <i>J Pediatr.</i> 1991;118(1):121-123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/1986079/pubmed" id="1986079" target="_blank">1986079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21920871">
<a name="21920871"></a>Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. <i>Arch Dis Child</i>. 2012;97(4):376-380.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/21920871/pubmed" id="21920871" target="_blank">21920871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2195347">
<a name="2195347"></a>Menon RK, Cohen RM, Sperling MA, et al. Transplacental Passage of Insulin in Pregnant Women With Insulin-Dependent Diabetes Mellitus. Its Role in Fetal Macrosomia. <i>N Engl J Med.</i> 1990;323(5):309-315.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/2195347/pubmed" id="2195347" target="_blank">2195347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19454396">
<a name="19454396"></a>Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. <i>Endocr Pract. </i>2009;15(4):353-369.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/19454396/pubmed" id="19454396" target="_blank">19454396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1711959">
<a name="1711959"></a>Morley JE and Perry HM 3d. The Management of Diabetes Mellitus in Older Individuals. <i>Drugs.</i> 1991;41(4):548-565.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/1711959/pubmed" id="1711959" target="_blank">1711959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mount.1">
<a name="Mount.1"></a>Mount DB. Treatment and prevention of hyperkalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33993515">
<a name="33993515"></a>Moussavi K, Garcia J, Tellez-Corrales E, Fitter S. Reduced alternative insulin dosing in hyperkalemia: a meta-analysis of effects on hypoglycemia and potassium reduction. <i>Pharmacotherapy</i>. 2021;41(7):598-607. doi:10.1002/phar.2596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/33993515/pubmed" id="33993515" target="_blank">33993515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31084947">
<a name="31084947"></a>Moussavi K, Fitter S, Gabrielson SW, Koyfman A, Long B. Management of hyperkalemia with insulin and glucose: pearls for the emergency clinician. <i>J Emerg Med</i>. 2019;57(1):36-42. doi:10.1016/j.jemermed.2019.03.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/31084947/pubmed" id="31084947" target="_blank">31084947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32426734">
<a name="32426734"></a>Moussavi K, Nguyen LT, Hua H, Fitter S. Comparison of IV insulin dosing strategies for hyperkalemia in the emergency department. <i>Crit Care Explor</i>. 2020;2(4):e0092. doi:10.1097/CCE.0000000000000092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/32426734/pubmed" id="32426734" target="_blank">32426734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mueller-Schoop.1">
<a name="Mueller-Schoop.1"></a>Mueller-Schoop J. Accidental Intravenous Self-Injection With Insulin Pen. <i>Lancet.</i> 1993;341(8849):894.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Myxredlin.1">
<a name="Myxredlin.1"></a>Myxredlin (insulin human) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Myxredlin.2">
<a name="Myxredlin.2"></a>Myxredlin (insulin human) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2224755">
<a name="2224755"></a>Nathan DM. Insulin Treatment in the Elderly Diabetic Patient. <i>Clin Geriatr Med.</i> 1990;6(4):923-931.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/2224755/pubmed" id="2224755" target="_blank">2224755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Newton.1">
<a name="Newton.1"></a>Newton L, Garvey WT, eds. Nutritional and medical management of diabetes mellitus in hospitalized patients. In: Mueller C, ed. In: Mueller CM, ed. <i>A.S.P.E.N. Adult Nutrition Support Core Curriculum.</i> 2nd edition. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2012:599.  http://www.nutritioncare.org/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19318384">
<a name="19318384"></a>NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. <i>N Engl J Med.</i> 2009;360(13):1283-1297. doi:10.1056/NEJMoa0810625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/19318384/pubmed" id="19318384" target="_blank">19318384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novolin.1">
<a name="Novolin.1"></a>Novolin ge (insulin regular) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; March 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novolin.2">
<a name="Novolin.2"></a>Novolin R (insulin regular) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15669878">
<a name="15669878"></a>Oiknine R, Bernbaum M, Mooradian AD. A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus. <i>Drugs.</i> 2005;65(3):325-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/15669878/pubmed" id="15669878" target="_blank">15669878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult basic and advanced life support writing group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):s366-s468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi:10.1007/s11695-012-0622-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Peters.1">
<a name="Peters.1"></a>Peters AP, Laffel L, eds. <i>Type 1 Diabetes Sourcebook</i>. American Diabetes Association; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS. Standardizing I.V. Infusion Concentrations: National Survey Results. <i>Am J Health Syst Pharm.</i> 2011;68(22):2176-2182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19636533">
<a name="19636533"></a>Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. <i>Intensive Care Med</i>. 2009;35(10):1738-1748. doi:10.1007/s00134-009-1585-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/19636533/pubmed" id="19636533" target="_blank">19636533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15251632">
<a name="15251632"></a>Proceedings of the American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control Consensus Conference. Washington, DC, USA, December 2003. <i>Endocr Pract</i>. 2004;10(suppl 2):3-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/15251632/pubmed" id="15251632" target="_blank">15251632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21320941">
<a name="21320941"></a>Qaseem A, Humphrey LL, Chou R, et al. Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians.<i> Ann Intern Med.</i> 2011;154(4):260-267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/21320941/pubmed" id="21320941" target="_blank">21320941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22312141">
<a name="22312141"></a>Qaseem A, Humphrey LL, Sweet DE, et al. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians. <i>Ann Intern Med.</i> 2012;156(3):218-231.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22312141/pubmed" id="22312141" target="_blank">22312141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29923163">
<a name="29923163"></a>Rawla P, Sunkara T, Thandra KC, Gaduputi V. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. <i>Clin J Gastroenterol</i>. 2018;11(6):441-448. doi:10.1007/s12328-018-0881-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/29923163/pubmed" id="29923163" target="_blank">29923163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28924481">
<a name="28924481"></a>Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. <i>Endocrinol Diabetes Metab Case Rep</i>. 2017;2017:17-0081. doi:10.1530/EDM-17-0081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/28924481/pubmed" id="28924481" target="_blank">28924481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15461903">
<a name="15461903"></a>Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/15461903/pubmed" id="15461903" target="_blank">15461903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14578243">
<a name="14578243"></a>Riddle MC, Rosenstock J, Gerich J, et al. The Treat-to-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients. <i>Diabetes Care.</i> 2003;26(11):3080-3086.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/14578243/pubmed" id="14578243" target="_blank">14578243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24143117">
<a name="24143117"></a>Rocchio MA, Belisle CD, Greenwood BC, Cotugno MC, Szumita PM. Evaluation of the maximum beyond-use-date stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. <i>Diabetes Metab Syndr Obes</i>. 2013;6:389-392.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/24143117/pubmed" id="24143117" target="_blank">24143117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12605114">
<a name="12605114"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive Pharmacologic Donor Management Results in More Transplanted Organs. <i>Transplantation</i>. 2003a;75(4):482-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/12605114/pubmed" id="12605114" target="_blank">12605114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12717226">
<a name="12717226"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. <i>Transplantation</i>. 2003b;75(8):1336-1341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/12717226/pubmed" id="12717226" target="_blank">12717226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243491">
<a name="12243491"></a>Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. <i>Am J Transplant</i>. 2002;2(8):701-711.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/12243491/pubmed" id="12243491" target="_blank">12243491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7040473">
<a name="7040473"></a>Sadur CN, Eckel RH. Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique. <i>J Clin Invest</i>. 1982;69(5):1119-1125. doi:10.1172/jci110547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/7040473/pubmed" id="7040473" target="_blank">7040473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17488392">
<a name="17488392"></a>Salim A, Martin M, Brown C, et al. Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation. <i>Clin Transplant.</i> 2007;21(3):405-409.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/17488392 /pubmed" id="17488392 " target="_blank">17488392 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22489323">
<a name="22489323"></a>Schafers S, Naunheim R, Vijayan A, Tobin G. Incidence of hypoglycemia following insulin-based acute stabilization of hyperkalemia treatment. <i>J Hosp</i>
<i>Med</i>. 2012;7(3):239-242. doi:10.1002/jhm.977<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22489323/pubmed" id="22489323" target="_blank">22489323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34957477">
<a name="34957477"></a>Schult RF, Nacca N, Grannell TL, Jorgensen RM, Acquisto NM. Evaluation of high-dose insulin/euglycemia therapy for suspected β-blocker or calcium channel blocker overdose following guideline implementation. <i>Am J Health Syst Pharm</i>. 2022;79(7):547-555. doi:10.1093/ajhp/zxab439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/34957477/pubmed" id="34957477" target="_blank">34957477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36161685">
<a name="36161685"></a>Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2022;23(7):872-902. doi:10.1111/pedi.13409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/36161685/pubmed" id="36161685" target="_blank">36161685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15616254">
<a name="15616254"></a>Silverstein J, Klingensmith G, Copeland K, et al. Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association. <i>Diabetes Care.</i> 2005;28(1):186-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/15616254/pubmed" id="15616254" target="_blank">15616254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8176576">
<a name="8176576"></a>Simeon PS, Geffner ME, Levin SR, et al. Continuous Insulin Infusions in Neonates: Pharmacologic Availability of Insulin in Intravenous Solutions. <i>J Pediatr. </i>1994;124(5, pt 1):818-820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/8176576/pubmed" id="8176576" target="_blank">8176576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smetzer.1">
<a name="Smetzer.1"></a>Smetzer J, Cohen M, eds. Medication errors during insulin administration for patients with hyperkalemia. <i>ISMP Medication Safety Alert! Acute Care</i>. 2018;23(3):1-5. https://www.ismp.org/resources/medication-errors-during-insulin-administration-patients-hyperkalemia
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31215460">
<a name="31215460"></a>Song X, Shi D, Cui Q, et al. Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): study protocol for a randomized controlled trial. <i>Trials</i>. 2019;20(1):365. doi:10.1186/s13063-019-3498-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/31215460/pubmed" id="31215460" target="_blank">31215460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28726299">
<a name="28726299"></a>Sundberg F, Barnard K, Cato A, et al. ISPAD guidelines. Managing diabetes in preschool children. <i>Pediatr Diabetes</i>. 2017;18(7):499-517.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/28726299/pubmed" id="28726299" target="_blank">28726299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22746979">
<a name="22746979"></a>Thompson CD, Vital-Carona J, Faustino EV. The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. <i>Diabetes Technol Ther</i>. 2012;14(10):912-916.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22746979/pubmed" id="22746979" target="_blank">22746979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22223765">
<a name="22223765"></a>Umpierrez GE, Hellman R, Korytkowski MT, et al; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(1):16-38. doi:10.1210/jc.2011-2098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22223765/pubmed" id="22223765" target="_blank">22223765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16452557">
<a name="16452557"></a>van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. <i>N Engl J Med</i>. 2006;354(5):449-461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/16452557/pubmed" id="16452557" target="_blank">16452557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11794168">
<a name="11794168"></a>van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. <i>N Engl J Med</i>. 2001;345(19):1359-1367.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/11794168/pubmed" id="11794168" target="_blank">11794168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956228">
<a name="20956228"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation.</i> 2010;122(18)(suppl 3):829-861. doi:10.1161/CIRCULATIONAHA.110.971069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/20956228/pubmed" id="20956228" target="_blank">20956228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Insulin therapy in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26762588">
<a name="26762588"></a>Wheeler DT, Schafers SJ, Horwedel TA, Deal EN, Tobin GS. Weight-based insulin dosing for acute hyperkalemia results in less hypoglycemia. <i>J Hosp Med</i>. 2016;11(5):355-357. doi:10.1002/jhm.2545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/26762588/pubmed" id="26762588" target="_blank">26762588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22500167">
<a name="22500167"></a>Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/22500167/pubmed" id="22500167" target="_blank">22500167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728267">
<a name="18728267"></a>Wiener RS, Wiener DC, Larson RJ. Benefits and Risks of Tight Glucose Control in Critically Ill Adults: A Meta-Analysis. <i>JAMA.</i> 2008;300(8):933-944.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/18728267/pubmed" id="18728267" target="_blank">18728267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29900641">
<a name="29900641"></a>Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):155–177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/29900641/pubmed" id="29900641" target="_blank">29900641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16644656">
<a name="16644656"></a>Wolfsdorf J, Glaser N, Sperling MA; American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: a consensus statement from the American Diabetes Association. <i>Diabetes Care</i>. 2006;29(5):1150-1159. doi:10.2337/diacare.2951150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/16644656/pubmed" id="16644656" target="_blank">16644656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12176957">
<a name="12176957"></a>Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus Conference Report: Maximizing Use of Organs Recovered from the Cadaver Donor: Cardiac Recommendations: March 28-29, 2001, Crystal City, Va. <i>Circulation</i>. 2002;106(7):836-841.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/12176957/pubmed" id="12176957" target="_blank">12176957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29999228">
<a name="29999228"></a>Zeitler P, Arslanian S, Fu J, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):28-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/29999228/pubmed" id="29999228" target="_blank">29999228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21035820">
<a name="21035820"></a>Zeitler P, Haqq A, Rosenbloom A, Glaser N; Drugs and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. <i>J Pediatr</i>. 2011;158(1):9-14. doi:10.1016/j.jpeds.2010.09.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-regular-pediatric-drug-information/abstract-text/21035820/pubmed" id="21035820" target="_blank">21035820</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12880 Version 312.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
